COVID-19 Citizen Science Expansion Project
Comparing Patient-reported Impact of COVID-19 Shelter-in-place Policies and Access to Containment and Mitigation Strategies, Overall and in Vulnerable Populations
1 other identifier
observational
54,689
1 country
9
Brief Summary
COVID-19 Citizen Science (CCS), launched in March 2020, supports collaborative research on symptoms, risk factors, surveillance, biomarkers and testing for COVID-19 using the Eureka Research Platform. CCS maintains IRB approval with UCSF's IRB (UCSF IRB# 17-21879). This CCS Expansion Project, which is funded jointly by the National Institutes of Health (NIH), the Patient-Centered Outcomes Research Institute (PCORI), and the Bill and Melinda Gates Foundation, will invite patients at health systems across the US to contribute their health records data and then join the established CCS study, allows for linked analysis of CCS data and health records data, and provides the scientific rationale and plan for the project.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2020
Typical duration for all trials
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 24, 2020
CompletedFirst Submitted
Initial submission to the registry
September 19, 2022
CompletedFirst Posted
Study publicly available on registry
September 21, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2024
CompletedNovember 1, 2024
October 1, 2024
3.8 years
September 19, 2022
October 29, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
GAD-7 anxiety score
Anxiety is measured in monthly surveys using the seven-item General Anxiety Disorder-7 (GAD-7) questionnaire. Responses to each item in the GAD-7 are scored as integer values between 0-3 according to the frequency of symptoms during the preceding two weeks ("Not at all", "Several days", "More than half the days", or "Nearly every day"). The sum of all seven items produces a combined score between 0-21, where scores ≥ 10 are considered indicative of moderate to severe anxiety disorders
Over the course of the pandemic, up to 5 years
Eligibility Criteria
Our goal will be to recruit a large sample of participants that is representative of the US population. In particular, we wish to make inferences about Hispanic/LatinX and African- American/Black subsets of the US population, who appear to be especially vulnerable to both direct (infection-related) and indirect impact of the Pandemic.
You may qualify if:
- Age ≥ 18 years
- Has the capacity to read and comprehend English
- Has internet access and a device (computer, tablet, laptop, etc.) that can access it
You may not qualify if:
- \. Unable or unwilling to provide informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of California, San Franciscolead
- Sutter Healthcollaborator
- Carelon Researchcollaborator
- Louisiana Public Health Institutecollaborator
- Duke Universitycollaborator
- New York Universitycollaborator
- Albert Einstein College of Medicinecollaborator
- University of Utahcollaborator
- Ochsner Health Systemcollaborator
- Baylor Scott and White Healthcollaborator
- Wake Forest University Health Sciencescollaborator
- New York City Health and Hospitals Corporationcollaborator
Study Sites (9)
Sutter Health
Sacramento, California, 95833, United States
University of California, San Francisco
San Francisco, California, 94158, United States
Advocate Aurora Health
Downers Grove, Illinois, 60515, United States
Ochsner Health System
New Orleans, Louisiana, 70121, United States
NYC Health + Hospitals
New York, New York, 10004, United States
New York University
New York, New York, 10016, United States
Albert Einstein College of Medicine
The Bronx, New York, 10467, United States
Baylor Scott and White Health
Dallas, Texas, 95246, United States
University of Utah
Salt Lake City, Utah, 84132, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mark Pletcher, MD, MPH
University of California, San Francisco
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 19, 2022
First Posted
September 21, 2022
Study Start
November 24, 2020
Primary Completion
September 1, 2024
Study Completion
September 1, 2024
Last Updated
November 1, 2024
Record last verified: 2024-10
Data Sharing
- IPD Sharing
- Will not share